About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker HRTX · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 13, 2026PK and Safety After C-Section
NCT03955211 · Postoperative Pain
HTX-011, ZYNRELEF kit components for administration
HRTX
Heron Therapeutics
Phase 2Completed25Dec 3, 2021Registry ↗
Oct 28, 2026Cohort 2 (Abdominoplasty) of: A Multi-surgery Assessment of ZYNRELEF (HTX-011)
NCT06109428 · Postoperative Pain, Abdominoplasty Surgery
MMA regimen, ZYNRELEF kit components for administration
HRTX
Heron Therapeutics
Phase 4Completed37Mar 29, 2022Registry ↗
Oct 28, 2026Bupivacaine HCl PK and Safety in Augmentation Mammoplasty
NCT03705065 · Postoperative Pain
Bupivacaine HCl
HRTX
Heron Therapeutics
Phase 4Completed30Oct 8, 2018Registry ↗
Oct 27, 2026Cohort 1 (TSA) of: A Multi-surgery Assessment of ZYNRELEF (HTX-011)
NCT06109415 · Postoperative Pain, Total Shoulder Arthroplasty
HTX-011, Bupivacaine Hydrochloride
HRTX
Heron Therapeutics
Phase 4Completed30Jul 18, 2022Registry ↗
Jul 17, 2026HTX-011 for Post-bunionectomy Analgesia
NCT02471898 · Analgesia
HTX-011, Placebo
HRTX
Heron Therapeutics
Phase 2Completed71Sep 2015Registry ↗
Jun 9, 2026Dose-Escalation Study of HTX-034 Following Bunionectomy
NCT04398329 · Bunions, Postoperative Pain
HTX-034 low dose, HTX-034 high dose
HRTX
Heron Therapeutics
Phase 1/2Completed78Jul 15, 2021Registry ↗
Jun 4, 2026Study of Post-Herniorrhaphy Non-opioid MMA Regimens
NCT03907176 · Analgesia
HTX-011, Luer lock applicator
HRTX
Heron Therapeutics
Phase 3Completed209Oct 25, 2021Registry ↗
May 12, 2026Pediatric Postoperative Analgesia Herniorrhaphy Study
NCT03922048 · Analgesia
HTX-011, Bupivacaine HCl
HRTX
Heron Therapeutics
Phase 2Withdrawn0Nov 2025Registry ↗
Mar 2, 2026Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)
NCT04470622 · COVID-19
Aprepitant injectable emulsion, Saline Placebo
HRTX
Heron Therapeutics
Phase 2Terminated27Apr 9, 2021Registry ↗
Mar 2, 2026Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen
NCT03974932 · Analgesia
HTX-011, Ibuprofen
HRTX
Heron Therapeutics
Phase 3Completed116Dec 7, 2020Registry ↗
Mar 2, 2026Phase 2 Bunionectomy HTX-011 Administration Study
NCT03718039 · Postoperative Pain
HTX-011, Luer Lock applicator
HRTX
Heron Therapeutics
Phase 2Completed78Jan 31, 2019Registry ↗
Mar 2, 2026Phase 2 Herniorrhaphy Study for Opioid Elimination
NCT03695367 · Postoperative Pain
HTX-011, Luer lock applicator
HRTX
Heron Therapeutics
Phase 2Completed63Nov 20, 2018Registry ↗
Mar 2, 2026Bunionectomy Study for Postoperative Analgesia (EPOCH 1)
NCT03295721 · Postoperative Pain
HTX-011, Saline Placebo
HRTX
Heron Therapeutics
Phase 3Completed412Jan 8, 2018Registry ↗
Mar 2, 2026Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)
NCT03237481 · Postoperative Pain
HTX-011, Bupivacaine HCl
HRTX
Heron Therapeutics
Phase 3Completed418Dec 22, 2017Registry ↗
Mar 2, 2026Total Knee Arthroplasty Infiltration Study for Postoperative Analgesia
NCT03015532 · Postoperative Pain
HTX-011, Saline Placebo
HRTX
Heron Therapeutics
Phase 2Completed285Apr 20, 2018Registry ↗
Mar 2, 2026Phase 2B Upper Extremity Nerve Block Study
NCT03011333 · Postoperative Pain
HTX-011, Bupivacaine HCl without epinephrine
HRTX
Heron Therapeutics
Phase 2Completed243Feb 1, 2018Registry ↗
Mar 2, 2026Evaluation of the Efficacy and Safety of HTX-011 for Postoperative Analgesia Following Abdominoplas…
NCT02689258 · Postoperative Pain
HTX-011B, Placebo
HRTX
Heron Therapeutics
Phase 2Completed277Mar 2017Registry ↗
Mar 2, 2026Pilot Herniorrhaphy Study for Postoperative Analgesia
NCT02504580 · Postoperative Pain
HTX-011, Placebo
HRTX
Heron Therapeutics
Phase 2Completed463Mar 2017Registry ↗
Mar 2, 2026A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Rec…
NCT02106494 · Chemotherapy-induced Nausea and Vomiting
APF530, Ondansetron
HRTX
Heron Therapeutics
Phase 3Completed942May 2015Registry ↗
Mar 2, 2026APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and V…
NCT00343460 · Nausea and Vomiting, Unspecified Adult Solid Tumor, Protoco…
APF530, dexamethasone
HRTX
Heron Therapeutics
Phase 3Completed1,428Sep 2008Registry ↗
Feb 23, 2026Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia F…
NCT02762929 · Postoperative Pain, Bunions
HTX-011A, Saline Placebo
HRTX
Heron Therapeutics
Phase 2Completed430Feb 2017Registry ↗
Feb 12, 2026A Phase I Study of the Effects of APF530 Exposure, Granisetron and Moxifloxacin
NCT01416259 · Healthy
Withdraw treatment
HRTX
Heron Therapeutics
—Completed56Oct 2011Registry ↗
Oct 26, 2023A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE. Master Protocol HTX-011-401.
NCT05109312 · Analgesia
Bupivacaine Hydrochloride, Bupivacaine Hydrochloride
HRTX
Heron Therapeutics
Phase 4Active, not recruiting90Jun 2024Registry ↗
Jul 28, 2023Safety Study of Repeat Doses of SUSTOL in Adults
NCT05434663 · Chemotherapy-Induced Nausea and Vomiting (CINV)
SUSTOL
HRTX
Heron Therapeutics
Phase 4Active, not recruiting300Oct 2025Registry ↗
Jun 12, 2023HTX-011 in Spinal Surgery
NCT04911062 · Post-Operative Pain, Lumbar Laminectomy
Bupivacaine HCI without epinephrine, HTX-011
HRTX
Heron Therapeutics
Phase 2Completed32Jul 29, 2022Registry ↗
Sep 26, 2019Extended Delivery of Bupivacaine Study in Herniorrhaphy
NCT04102267 · Analgesia
Bupivacaine liposome injectable suspension, Bupivacaine HCl…
HRTX
Heron Therapeutics
Phase 4Completed32Sep 3, 2018Registry ↗

26 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:51 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances